Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 10.46
-0.18 (-1.69%)
Jul 30, 2026, 9:25 AM CST
SHE:301211 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 459.02 | 453.31 | 445.86 | 663.03 | 514.91 | 540.62 |
Revenue Growth | 8.71% | 1.67% | -32.75% | 28.77% | -4.76% | -8.82% |
Gross Profit Gross Profit Growth | 94.66 | 94.9 | 128.07 | 265.47 | 145.13 | 182.3 |
Operating Income Operating Income Growth | 0.19 | -0.19 | 29.64 | 145.4 | 75.35 | 118.06 |
Net Income Net Income Growth | 33.8 | 34.91 | 91.55 | 176.12 | 125.79 | 121.65 |
Earnings Per Share EPS Growth | 0.08 | 0.08 | 0.22 | 0.42 | 0.30 | 0.39 |
EPS Growth | -45.29% | -63.64% | -47.71% | 38.66% | -22.36% | -26.88% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Active Pharmaceutical Ingredient (API) Active Pharmaceutical Ingredient (API) Growth | 338.34 | 356.16 | 554.61 | 426.89 | 464.61 |
Preparations Preparations Growth | 107.46 | 85.21 | 103.38 | 86.47 | 75.13 |
Others Others Growth | 7.5 | 4.49 | 5.04 | 1.56 | 0.87 |
Total Total Growth | 453.31 | 445.86 | 663.03 | 514.91 | 540.62 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 1,540 | 1,555 | 1,637 | 1,824 | 1,962 | 1,860 |
Total Debt Total Debt Growth | 2.35 | 3.13 | 5.22 | 6.66 | 7.4 | - |
Net Cash (Debt) Net Cash Growth | 1,538 | 1,552 | 1,631 | 1,817 | 1,955 | 1,860 |
Net Cash Growth | -5.00% | -4.88% | -10.22% | -7.04% | 5.10% | 438.28% |
Net Cash Per Share Net Cash Per Share Growth | 3.64 | 3.56 | 3.92 | 4.34 | 4.71 | 5.97 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -0.97 | 7.55 | 96.07 | 137.06 | 250.79 | 123.98 |
Capital Expenditures CapEx Growth | -44.75 | -52.33 | -164.43 | -186.53 | -75.95 | -21.07 |
Free Cash Flow Free Cash Flow Growth | -45.72 | -44.78 | -68.36 | -49.47 | 174.84 | 102.92 |
Free Cash Flow Growth | - | - | - | - | 69.89% | -4.96% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 20.62% | 20.93% | 28.73% | 40.04% | 28.18% | 33.72% |
Operating Margin | 0.04% | -0.04% | 6.65% | 21.93% | 14.63% | 21.84% |
Pretax Margin | 8.50% | 9.10% | 22.52% | 30.59% | 28.63% | 25.75% |
Profit Margin | 7.36% | 7.70% | 20.53% | 26.56% | 24.43% | 22.50% |
FCF Margin | -9.96% | -9.88% | -15.33% | -7.46% | 33.96% | 19.04% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.060 | 0.060 | 0.250 | 0.331 | 0.230 | 0.172 |
Dividend Per Share Growth | -65.20% | -76.00% | -24.47% | 43.98% | 33.35% | - |
Dividend Yield | 0.56% | 0.49% | 1.74% | 2.32% | 1.23% | 0.86% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 130.75 | 146.18 | 66.88 | 35.57 | 66.11 | 74.20 |
P/FCF Ratio | - | - | - | - | 47.56 | 87.71 |
PS Ratio | 9.52 | 11.26 | 13.73 | 9.45 | 16.15 | 16.70 |